ARCHIVES

An old drug’s 21st century makeover begins with 84-fold price increase. Price hike of procarbazine astonishes brain tumor specialists.

This article is from The Cancer Letter archive.

Vol. 31 No. 19 | May 13, 2005

Download PDF Visit The Full Archive

Related Articles

340B Drug Discount Program: HRSA Defends Orphan Drug Rule

June 20, 2014

DCE Makes Changes In Procedure For Occupational Studies

November 21, 1986

Impetus to Proceed with a March Came From Talk Show

October 31, 1997

Senate Investigates Opioid Manufacturers, Requests Study of Impact of DEA Policies

May 11, 2012

NCI Proposes Extension Of Breast Cancer Screening To Determine Efficacy Of Biennial Tests

November 7, 1975

NCI Programs: Study Finds Bomb Tests Raised I-131 Exposure in 1950’s, 1960’s

August 22, 1997